Sobreuso de ecografía transvaginal en un hospital universitario privado de Argentina: estudio de corte transversal / Transvaginal ultrasound overuse in a private university hospital in Argentina: a cross-sectional study

Introducción. Si bien contamos con recomendaciones basadas en la evidencia en contra de realizar tamizaje de cáncer ovárico con ecografía transvaginal debido a que aumenta el riesgo de resultados falsamente positivos y de cascadas diagnósticas, sin disminuir la mortalidad por esta enfermedad, su solicitud en mujeres sanas es frecuente. Sin embargo, no conocemos la magnitud de la implementación de esta práctica, que constituye un cuidado de bajo valor. Objetivo. Documentar el sobreuso de ecografías transvaginales realizadas en forma ambulatoria en un hospital universitario privado de Argentina. Métodos. Estudio de corte transversal de una muestra aleatoria de ecografías realizadas en forma ambulatoria durante 2017 y 2018. Mediante revisión manual de las historias clínicas, la solicitud de cada ecografía fue clasificada como apropiada cuando algún problema clínico justificaba su realización, o inapropiada cuando había sido realizada con fines de control de salud o por una condición clínica sin indicación de seguimiento ecográfico. Resultados. De un total de 1.997 ecografías analizadas, realizadas a 1.954 mujeres adultas (edad promedio 50 años),1.345 (67,4 %; intervalo de confianza [IC] 95 % 65,2 a 69,4) habían sido solicitadas en el contexto de un control de saludo sin un problema asociado en la historia clínica y otras 54 (8,3 %; IC 95 % 6,3 a 10,7), por condiciones de salud para las que no hay recomendaciones de realizar seguimiento ecográfico. Conclusiones. Esta investigación documentó una alta proporción de sobre utilización de la ecografías transvaginales en nuestra institución. Futuras investigaciones permitirán comprender los motivos que impulsan esta práctica y ayudarán a diseñar intervenciones para disminuir estos cuidados de bajo valor. (AU)

Background. Although we have evidence-based recommendations against screening for ovarian cancer with transvaginalultrasound because it increases the risk of false positive results and diagnostic cascades without reducing mortality from this disease, its request in healthy women is frequent. However, we do not know the magnitude of the implementation of this practice, which constitutes low-value care. Objective. To document the overuse of transvaginal ultrasounds performed on an outpatient basis in a private university hospital in Argentina. Methods. Cross-sectional study of a random sample of outpatient ultrasounds performed during 2017 and 2018. Through a manual review of the medical records, the request for each ultrasound was classified as appropriate when a clinical problem justified its performance or inappropriate when it was carried out for health control purposes or for a clinical condition that had no indication for ultrasound follow-up. Results. Of a total of 1997 ultrasounds analyzed, performed on 1954 adult women (average age 50 years), 1,345 (67.4 %;95 % confidence interval [CI] 65.2 to 69.4) had been requested in the context of a health check-up or without a documented problem in the medical history that would support its performance, and another 54 (8.3 %; 95 % CI 6.3 to 10.7), for health conditions for which there are no treatment recommendations to perform ultrasound follow-up. Conclusions. This research documented a high proportion of overuse of transvaginal ultrasound in our institution. Future research will allow us to understand the reasons that drive this practice and will help design interventions to reduce thislow-value care. (AU)

Salpingectomía oportunista: patrones de práctica en un grupo de ginecólogos colombianos / Opportunistic Salpingectomy: patterns of practice in a group of colombian gynecologists

INTRODUCCIÓN Y OBJETIVOS: El cáncer de ovario es la neoplasia de origen ginecológico más letal y el 90% de los casos son de origen epitelial. Se ha postulado el origen del cáncer epitelial de ovario (CEO) en las fimbrias de las trompas de Falopio, por lo cual, se ha sugerido la realización de la salpingectomía oportunista como método de prevención primaria. La presente investigación tiene como objetivo determinar la frecuencia con que los ginecólogos adscritos a la Federación Colombiana de Ginecología y Obstetricia (FECOLSOG) incluyeron salpingectomías oportunistas en su práctica clínica durante los años 2017-2018. MÉTODOS: Se realizó una encuesta a los ginecólogos adscritos a la FECOLSOG. Las variables analizadas incluyeron características demográficas, práctica profesional, método de prevención primaria de cáncer de ovario en pacientes de bajo riesgo y la realización o no de la salpingectomía oportunista y sus respectivas razones. Las variables cualitativas se analizaron con frecuencias absolutas y relativas, mientras que las cuantitativas con medidas de tendencia central y desviaciones estándar con el software STATA 13. RESULTADOS: De 1765 ginecólogos contactados, 353 contestaron la encuesta (tasa de respuesta del 20%). El 62.5% de estos realizan salpingectomía oportunista en su práctica ginecológica y de estos, el 75.2% lo hizo para prevenir cáncer de ovario. Entre las razones manifestadas por los especialistas para no realizar salpingectomía oportunista, el 12.5% no la consideraba un factor de protección frente al cáncer de ovario y un 14.4% consideraba que incrementaba el riesgo de falla ovárica temprana y morbilidad asociada. CONCLUSIÓN: Aunque existen controversias en su realización, la salpingectomía oportunista muestra ser una conducta adoptada por ginecólogos adscritos a FECOLSOG. Se requieren investigaciones futuras para determinar la efectividad de la salpingectomía e implementar estrategias de prevención del cáncer epitelial de ovario.

INTRODUCTION AND OBJECTIVES: Ovarian cancer is the most lethal gynecological malignancy and 90% of cases are of epithelial origin. Recently, different investigations attribute their origin to the fimbriae of the fallopian tubes, reason why it has been suggested to perform elective salpingectomy for the prevention of high-grade adenocarcinoma, its most frequent histological variant. This research aims to determine the frequency with which gynecologists from the Colombian Federation of Gynecology and Obstetrics (FECOLSOG) included this procedure in their clinical practice during the years 2017-2018. METHODS: A survey was sent electronically to the gynecologists assigned to FECOLSOG on three different occasions with an interval of 15 days between them. The variables analyzed included demographic characteristics, professional practice, primary prevention method of Ovarian Cancer in low-risk patients and the performance or not of elective salpingectomy with their respective reasons. Qualitative variables were analyzed with absolute and relative frequencies, while quantitative variables with measures of central tendency and standard deviations with STATA 13 software. RESULTS: From 1765 gynecologists contacted at least once via email, 353 answered the survey, indicating a response rate of 20%. 62.5% perform elective salpingectomy in their gynecological practice and of these, 75.2% do so to prevent ovarian cancer. Among the reasons for not practicing salpingectomy, 12.5% ​​do not consider it a protective factor for ovarian cancer, and 14.4% believe that it increases the risk of early ovarian failure and morbidity. CONCLUSION: Elective salpingectomy is a promising procedure as a preventive measure against epithelial ovarian cancer. Although there are controversies regarding its performance, salpingectomy seems to be a common practice amongst gynecologists from FECOLSOG, and seems to have higher recurrence within this field. Future research is required to determine the effectiveness of salpingectomy and thus, implement the best strategies for ovarian cancer prevention.

Epidemiologia de cáncer de ovario colombia 2009- 2016 / Epidemiology of ovarian cancer colombia 2009- 2016

Resumen Introducción el cáncer es una de las enfermedades más temidas por la humanidad y el tumor maligno de ovario no es la excepción. Se caracteriza por su alta agresividad y por presentar síntomas inespecíficos, además de no contar, hasta el momento, con pruebas de tamizaje que permitan una detección precoz, convirtiéndose en uno de los cánceres femeninos con alta mortalidad ocupando el séptimo lugar a nivel mundial. Objetivo Medir la prevalencia, mortalidad y la letalidad asociadas al cáncer de ovario entre 2009 a 2016 en la población colombiana. Método se realizó un estudio descriptivo, transversal, ecológico. A partir de una base de datos en el RIPS de SISPRO y DANE se seleccionaron las mujeres con diagnóstico de tumor maligno de ovario. Resultados se hallaron 36.798 mujeres con diagnóstico de cáncer de ovario, la edad media fue de 63 años con una prevalencia de 31,66 por 100.000 mujeres, en los departamentos de Antioquia, Santander, y Bogotá. Se estimó una tasa de mortalidad de 3,9 por 100.000 mujeres, predominio en educación básica primaria, y régimen de seguridad social contributivo. La letalidad fue de 15,75%. Conclusiones En Colombia la prevalencia, mortalidad y letalidad entre 2009 a 2016 presentó una tendencia al incremento, predominio en casadas, bajo nivel educativo y menor acceso a los servicios de salud. En virtud de lo anteriormente expuesto, se abre la posibilidad de establecer prioridades sanitarias, diseño de futuras estrategias en prevención de la enfermedad en salud pública, detención precoz y con la consecuente disminución de la mortalidad.

Rastreamento do câncer de ovário / Screeening for ovarian cancer

Introdução: O câncer de ovário é uma das neoplasias com maior mortalidade no mundo. Esse dado se deve ao estágio avançado em que o tumor se encontra quando é diagnosticado. Em virtude disso, muitas pesquisas buscam métodos eficientes de rastreio para um diagnóstico e tratamento precoces. Métodos: Foi realizada a revisão sobre paciente com alto risco de câncer de ovário utilizando como base de dados o Pubmed, do qual foram selecionados artigos dos últimos 5 anos, com foco em revisões sobre rastreio e manejo dessas pacientes. Foi realizado consulta ao livro "Ginecologia básica e avançada" do Serviço de Ginecologia do Hospital São Lucas da PUCRS e aos sites do INCA e NCCN. Resultados: Nas análises reunidas, observou-se resultados desfavoráveis à realização dos exames para rastreio de câncer de ovário em paciente de baixo risco. Os estudos que mostram benefício intervencionista são os que avaliam o manejo cirúrgico em pacientes de alto risco para o desenvolvimento dessa neoplasia. Conclusão: Concluímos com a pesquisa realizada que não há evidências que justifiquem a aplicação de teste de rastreio para câncer de ovário para pacientes de baixo risco. Todavia, a cirurgia de salpingo-ooforectomia redutora de risco é recomendada em paciente com alto risco por apresentar significativa redução de mortalidade.

Introduction: Ovarian cancer is a very aggressive neoplasms. This is due to the advanced stage in which the tumor is found when it is diagnosed. As a result, many researches seek efficient screening methods for early diagnosis and treatment. Methods: The review was carried out on patients at high risk of ovarian cancer using a database Pubmed, from which articles were selected from the last 5 years, focusing on reviews on the screening and management of these patients. A consultation was made to the book "Ginecologia Básica e Avançada" of the Gynecology departament of the Hospital São Lucas da PUCRS and to the websites of INCA and NCCN. Results: In the analyzes, unfavorable results were observed in the ovarian cancer screening in a low-risk patient. Studies that show interventional benefit are those that evaluated the surgical management in patients at high risk for the development of this neoplasia. Conclusion: It was observed in the analysis that the studies still do not exist evidence that justify the application of screening test for ovarian cancer for patients of low risk. However, risk-reducing salpingo-oophorectomy surgery is recommended in a high-risk patient because of a significant reduction in mortality.

Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation

ABSTRACT OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study's cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country's health policies.

Is ovarian cancer prevention currently still a recommendation of our grandparents? / A prevenção do câncer de ovário ainda é uma recomendação de nossos avós?

Abstract Ovarian cancer is the leading cause of death among gynecologic tumors because in most of the cases (75%), the disease is diagnosed in advanced stages. Screening methods are not available since the disease is rare, and the tested methods, such as ultrasound and CA125, were not able to decrease the mortality rate for this type of cancer. This article discusses the main risk factors for ovarian cancer, and the potential clinical and surgical strategies for the prevention of this disease.

Resumo O câncer de ovário é a principal causa de morte entre os tumores ginecológicos, já que na maioria dos casos (75%) o diagnóstico ocorre em estádios avançados. Métodos de rastreamento não estão disponíveis, já que a doença é rara, e osmétodos diagnósticos, como ultrassonografia e CA 125, não são capazes de reduzir a taxa de mortalidade desse câncer. Este artigo discute os principais fatores de risco para o câncer de ovário e as possíveis estratégias clínicas e cirúrgicas para a prevenção dessa doença.

Caracterización de las pacientes con cáncer de ovario. Hospital Gineco-Obstétrico "Ramón González Coro" 2001-2013 / Characterization of patients with ovarian cancer. Gyneco-obstetric Hospital "Ramón González Coro" 2001-2013

Introducción: actualmente en Cuba y en todo el mundo, el cáncer de ovario representa la octava causa más importante de neoplasias malignas en la mujer, pero es la cuarta causa relacionada con la mortalidad. Objetivo: identificar el comportamiento por tipos histológicos y por tratamientos del cáncer de ovario. Materiales y métodos: se realizó un estudio descriptivo, retrospectivo, de pacientes con cáncer de ovario, atendidas en el Hospital "Ramón González Coro", La Habana. En el período comprendido entre enero de 2001 a julio de 2013. Las unidades de análisis fueron las historias clínicas de las 98 pacientes que se estudiaron. Resultados: se observó que 69,3 % tenían entre 31 y 60 años de edad. La edad promedio del grupo completo fue 48,2 años, la mitad de las pacientes no refirieron antecedentes patológicos. La paridad promedio fue 1,3. En 3,1 % tenían antecedentes de una neoplasia maligna confirmada y tratada, 14,3 % poseían antecedentes familiares maternos de neoplasia maligna; siendo el motivo de consulta más frecuente el "dolor en bajo vientre" (40,8 %). No hubo asociación significativa entre los estadios (FIGO) y el tipo de cáncer. Conclusiones: los resultados obtenidos se comportan, en general, de acuerdo a patrones epidemiológicos reportados internacionalmente, aunque la frecuencia de cáncer epitelial fue menor que la referida en la literatura consultada. La mayoría de los cánceres estudiados estaban en estadios I y III (AU).

Background: currently in Cuba and around the world, the ovarian cancer represents the eighth most important cause of malignant neoplasia in women, but it is the fourth cause related with mortality. Objective: identifying behavior by histological types and by ovarian cancer treatment. Materials and methods: a descriptive, retrospective study was carried out in patients with ovarian cancer attended in the Hospital "Ramón González Coro", Havana, in the period between January 2001 and July 2013. The analysis units were the clinical records of the 98 studied patients. Outcomes: it was observed that 69.3 % were aged 31-60 years. The average age of the entire group was 48.2 years; half of the patients did not refer pathological antecedents. The average parity was 1.3. 3.1 % had antecedents of confirmed and treated malignant neoplasia; 14.3 % had maternal antecedents of malignant neoplasia, being the most frequent motive of consultation "pain in the low womb" (40.8 %). There was not significant association between the stages (FIGO) and the cancer type. Conclusions: the obtained results behave, in general, according to the epidemiological patterns internationally reported, though the frequency of the epithelial cancer was lower than the one referred in the consulted literature. Most of the studied cancers were in stages I and III (AU).

Salpingectomia "oportuna" como profilaxia do câncer de ovário / "Timely" salpingectomy for ovarian cancer prophylaxis

O câncer de ovário é o tumor ginecológico mais letal, alvo de interesse de centenas de estudos publicados anualmente, buscando melhor entendimento fisiopatológico e a possibilidade de métodos de rastreio. Trata-se da quinta causa de morte por câncer em mulheres, sendo, na maioria das vezes, encontrado em estágios avançados. Existem diversas teorias sobre a origem do câncer de ovário, sendo uma delas a de que a neoplasia ovariana teria sua origem nas tubas uterinas. Sendo assim, estudos sugerem que a exérese das tubas uterinas poderia reduzir a incidência da neoplasia maligna ovariana. A proposta do artigo é realizar uma revisão sobre a salpingectomia bilateral durante cirurgias pélvicas eletivas e suas implicações na qualidade de vida da paciente, seu potencial preventivo e possíveis complicações.(AU)

Ovarian cancer is the most lethal gynecological tumor. Hundreds of manuscripts are annually published, aiming better pathophysiological understanding and screening strategies. Ovarian cancer is the fifth of cancer death in women worldwide and, in most times, the diagnosis is performed in advanced stages. There are several theories about the origin of ovarian cancer, one of which is that the ovarian cancer would have their origin in the fallopian tubes. Thus, current research suggests that the removal of the tubes could reduce the incidence of ovarian malignancy. The purpose of the article is to review of the bilateral salpingectomy during elective pelvic surgeries and their implications for the quality of life of the patient, its preventive potential and possible complications.(AU)

Major clinical research advances in gynecologic cancer in 2015 / 부인종양

In 2015, fourteen topics were selected as major research advances in gynecologic oncology. For ovarian cancer, high-level evidence for annual screening with multimodal strategy which could reduce ovarian cancer deaths was reported. The best preventive strategies with current status of evidence level were also summarized. Final report of chemotherapy or upfront surgery (CHORUS) trial of neoadjuvant chemotherapy in advanced stage ovarian cancer and individualized therapy based on gene characteristics followed. There was no sign of abating in great interest in immunotherapy as well as targeted therapies in various gynecologic cancers. The fifth Ovarian Cancer Consensus Conference which was held in November 7–9 in Tokyo was briefly introduced. For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was reviewed. For corpus cancer, the safety concern of power morcellation in presumed fibroids was explored again with regard to age and prevalence of corpus malignancy. Hormone therapy and endometrial cancer risk, trabectedin as an option for leiomyosarcoma, endometrial cancer and Lynch syndrome, and the radiation therapy guidelines were also discussed. In addition, adjuvant therapy in vulvar cancer and the updated of targeted therapy in gynecologic cancer were addressed. For breast cancer, palbociclib in hormone-receptor-positive advanced disease, oncotype DX Recurrence Score in low-risk patients, regional nodal irradiation to internal mammary, supraclavicular, and axillary lymph nodes, and cavity shave margins were summarized as the last topics covered in this review.

Cáncer serosopélvico de alto grado: evidencia sobre su origen en la trompa de Falopio / High-grade serous pelvic cancer: evidence of its origin in the fallopian tube

Cáncer epitelial de ovario es una enfermedad altamente letal. Constituye la quinta causa de muerte por cáncer en mujeres a nivel mundial. El subtipo histológico más frecuente es el carcinoma seroso de alto grado. Este es el responsable de la alta letalidad de la enfermedad. Se presenta evidencia que respalda el origen tubario de este tipo histológico desde lesiones precursoras. A partir de estos datos se ha establecido que el cáncer tradicionalmente conocido como cáncer ovárico seroso de alto grado, el cáncer de trompa de Falopio y el carcinoma peritoneal primario, corresponden a una misma entidad nosológica: cáncer seroso pélvico de alto grado. Se revisa además la evidencia disponible para establecer que la salpingectomía podría constituir una medida de prevención para este tipo de cáncer.

Epithelial ovarian cancer is a highly lethal disease. It is the 5th cause of cancer death in women worldwide. The most common histologic subtype is the high-grade serous carcinoma. This is the responsible for the high lethality of the disease. Evidence supporting the tubal origin of this histological type from precursor lesions is presented. From these data it has been established that cancer traditionally known as serous high-grade ovarian cancer, cancer of the fallopian tube and primary peritoneal carcinoma, correspond to a single disease entity: pelvic serous high-grade cancer. We also check the available evidence to establish that the salpingectomy could be a preventive measure for this type of cancer.

Estudo de mutações pontuais de BRCA1, BRCA2, CHEK2 e TP53 em pacientes com alto risco para câncer de mama e ovário hereditário / Study of point mutations of BRCA1, BRCA2, CHEK2, and TP53 in patients at high risk for hereditary breast and ovarian cancer

INTRODUÇÃO: BRCA1, BRCA2, CHEK2 e TP53 são os principais genes supressores tumorais associados às síndromes de câncer de mama e ovário hereditário (HBOC) e Li-Fraumeni (LFS/LFL). Em cânceres hereditários, a frequência de mutações em genes de baixa penetrância, como CHEK2, está entre 1-10%, entretanto nos genes de alta penetrância, como BRCA1/2 e TP53, a frequência é <1%. Até o momento, estudos feitos no Brasil apenas descreveram apenas o perfil de susceptibilidade genética de populações das regiões sul/sudeste. OBJETIVO: Analisar a ancestralidade e oito mutações dos genes BRCA1, BRCA2, CHEK2 e TP53 em 102 pacientes com alto risco para HBOC do Nordeste do Brasil...

INTRODUCTION: BRCA1, BRCA2, CHEK2 and TP53 are the mainly tumor suppressor genes associated with Hereditary Breast and Ovarian Cancer (HBOC) and Li-Fraumeni (LFS/LFL) syndromes. In hereditary cancers the frequency of mutations in susceptibility genes of low penetrance like CHEK2 is 1-10%, while in genes of high penetrance as BRCA1/2 and TP53 is <1%. Until now, the studies done in Brazil only described the susceptibility profile of populations from the south/southeast regions. OBJECTIVE: To analyze the ancestry and eight mutations of BRCA1, BRCA2, CHEK2 and TP53 genes in 102 patients at high-risk for HBOC from the Northeast of Brazil...

Carcinoma endometroide con áreas semejantes a tumor estromal de cordones sexuales / Endometrioid carcinoma with similar areas of sex cord stromal tumor

Conocido antiguamente como el "asesino silencioso", el cáncer de ovario muestra un espectro de síntomas inespecíficos que, una vez reconocidos, facilitan un diagnóstico temprano y prolongan la supervivencia de la paciente. Se presenta el caso de una paciente de 57 años referida de consulta privada por sangrado post menopaúsico con US transvaginal que revela datos de malignidad ovárica, laboratorios de rutina y marcadores tumorales normales...

Predisposición genética para el cáncer de mama: genes BRCA1 y BRCA2 / Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes

El descubrimiento de los genes BRCA1 y BRCA2 ha llevado a la introducción de pruebas genéticas cada vez más sofisticadas para medir el riesgo de cáncer de mama de origen hereditario, entre otras cosas. En el presente artículo exploramos los criterios a seguir para realizar pruebas para estos genes, así como las implicaciones en el tratamiento para los pacientes en caso de identificarlos.

The discovery of genes BRCA1 and BRCA2 has led to the introduction of genetic tests more complex every time for the evaluation ofthehereditarycancerrisk,amongothers.In the present paper we explore the criteria to decide when to run the testing for the genes, as well as the implications for the treatment of patients who are identified with them.

Diferencia en parámetros nutricionales de pacientes con tumores de ovario (benigno vs. maligno) / Difference in nutritional parameters of patients with ovarian tumors (benign vs. malignant)

Justificación: El cáncer de ovario es una enfermedad silenciosa, cuyo diagnóstico generalmente se realiza cuando la enfermedad se encuentra en etapas avanzadas. La finalidad de este estudio, es encontrar las posibles diferencias del estado nutricional al ingreso, de las pacientes con diagnóstico de tumor de ovario, y así poder tener más elementos para el diagnóstico temprano, que precedan el resultado de patología. Permitiendo anticipar las medidas nutricionales y terapéuticas con respecto a tipo histología benigna o maligna del tumor...

Cánceres ginecológicos y colorectal: riesgos y beneficios con el uso de anticonceptivos / Gynecological and colorectal cancers: risks and benefits with contraceptive use

Los cánceres genecológicos y colorectales se asocian a nivel mundial a importantes tasas de morbilidad y mortalidad. Tanto en estudios de cohorte, como de casos y controles se ha establecido una disminución del riesgo para los cánceres ginecológicos y colorectal asociado al uso de algunos métodos anticonceptivos (MAC)...

Síndromes familiares de câncer de mama e ovário / Familial syndrome of breast and ovarian cancer

A síndrome de câncer de mama e ovário hereditário é responsável por, aproximadamente, 5 a 10% dos casos de câncer neste órgãos, sendo que 80% destes tumores apresentam mutações nos genes BRCA1 e BRCA2. Atualmente, temos a possibilidade de realizar teste genético para detectar estas mutações em algumas pacientes com indicação. É importante saber quais pacientes seriam beneficiadas com o teste e se devem ou não receber profilaxa.

Actualización y combinación de las guías de cuidados preventivos de la fuerza de tareas de EE.UU. y Canadá: cuarta parte / Combination and update of preventive care guildelines of the U.S. and Canadian task forces: fourth part

La Fuerza de Tareas Preventiva de los EE.UU. (sigla en inglés: USPSTF) y la Fuerza de Tareas Canadiense de Cuidados Preventivos de la Salud (sigla en inglés: CTFPHC) son las dos instituciones más importantes del mundo en la evaluación de cuidados preventivos. Ambas emiten y actualizan constantemente recomendaciones preventivas; y las mismas pueden accederse en forma completa y gratuita a través de sus sitios Web (http://www.ahrq.gov/clinic/cps3dix.htm, y http://www.ctfphc.org). En esta cuarta entrega continuamos con la actualización de las prácticas preventivas referidas al rastreo del cáncer y su justificación clínica emitida por ambas entidades, respecto de aquellas previamente resumidas en el 2003[1] y en el 2005/6[2], [3] en Evidencia. Estas habían alcanzado las recomendaciones generadas hasta septiembre de 2005; lo cual implica la actualización o incorporación de aquellas recomendaciones aquí publicadas con fecha posterior. Muchas recomendaciones emitidas hace varios años se encuentran bajo revisión pero las mantenemos a título informativo hasta que los cambios sean confirmados.